The review, published on Oct. 12 in the Journal of the American College of Cardiology, noted five types of heart medications that can have severe adverse effects when combined with Paxlovid.
The five medication types are:
- Antiarrhythmic agents
- Antiplatelet agents and anticoagulants
- Certain statins
- Ranolazine
- Immunosuppressive agents
“Awareness of the presence of drug-drug interactions of Paxlovid with common cardiovascular drugs is key. System-level interventions by integrating drug-drug interactions into electronic medical records could help avoid related adverse events,” Sarju Ganatra, MD, director of the cardio-oncology program at Lahey Hospital and Medical Center in Burlington, Mass., and the senior author of the review, said in the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
